




The relative strengths and weaknesses of CTI Biopharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI Biopharma CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 2.4% points. The greatest weakness of CTI Biopharma CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 111% points below the market average of 252%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	46,924	Assets	54,886
Cost of Goods Sold	0	Liabilities	38,796
Intangible Assets	0	Expenses	64,665
Liabilities, Current	19,258	Revenues	25,146
Liabilities, Non-Current	19,044	Stockholders Equity	16,090
Other Assets	5,597	Net Income	-40,831
Other Compr. Net Income	544	Comprehensive Net Income	-40,559
Other Expenses	364	BaseVar	92,674
Other Liabilities	494	ECR before LimitedLiability	-12%
Other Net Income	-1,312	Economic Capital Ratio	141%
Other Revenues	25,146		
Property and Equipment	2,365		
Research and Development	32,866		
Selling, General and Administrative Expense	31,435		